0001209191-22-016050.txt : 20220303
0001209191-22-016050.hdr.sgml : 20220303
20220303211926
ACCESSION NUMBER: 0001209191-22-016050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220301
FILED AS OF DATE: 20220303
DATE AS OF CHANGE: 20220303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Konidaris Tasos
CENTRAL INDEX KEY: 0001320982
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 22711845
MAIL ADDRESS:
STREET 1: 103 JFK PARKWAY
CITY: SHORT HILLS
STATE: NJ
ZIP: 07078
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-01
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001320982
Konidaris Tasos
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
0
1
0
0
Executive Vice President & CFO
Class A Common Stock
2022-03-01
4
M
0
36197
A
123916
D
Restricted Stock Units
2022-03-01
4
M
0
36197
0.00
D
Class A Common Stock
36197
108591
D
Restricted Stock Units
2022-03-03
4
A
0
181159
0.00
A
Class A Common Stock
181159
181159
D
Performance-Based Restricted Stock Units
2022-03-03
4
A
0
362318
0.00
A
Class A Common Stock
362318
362318
D
Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
The restricted stock units vest in four equal annual installments beginning on March 3, 2023.
Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period.
/s/ Meredith Cook, Attorney-in-Fact
2022-03-03